Esphera SynBio operates as a biotechnology company. Esphera SynBio provides practitioners of synthetic biology for the treatment and prevention of disease.
Hyivy Health creates an intelligent and holistic pelvic rehabilitation device for the 1 in 3 women worldwide who will experience a pelvic health complication in their lifetime. Our device provides the first quantifiable data set on the pelvic floor and 3 different therapies from multiple sensors and mechanical functions to help keep track of progress, adapt treatment plans and provide more effective, comfortable rehab experiences.
Radiant Biotherapeutics is an innovative company focused on developing a modular platform for multi-valent and multi-specific therapeutics. This platform aims to advance antibody engineering by producing multi-functional biologics capable of addressing challenging diseases, including cancer, autoimmune disorders, and infectious diseases. By leveraging enhanced binding power and multi-specificity, Radiant Biotherapeutics seeks to create potent therapeutics that have the potential to significantly improve treatment outcomes for patients. The company is committed to delivering transformative therapies through its cutting-edge approach to antibody technology.
HDAX Therapeutics is focused on developing innovative small molecule therapeutics aimed at treating conditions driven by HDAC6, particularly in the realms of cardiovascular and neurological diseases. By addressing the root causes of these conditions, the company seeks to improve patient outcomes significantly. Their approach involves a unique targeted therapeutics platform that utilizes a two-site binding mechanism for HDAC6, which allows for the delivery of treatments that are both safe and effective. This strategy is designed to meet the substantial unmet medical needs associated with neuropathies and cardiometabolic diseases.
Tenomix mission is to develop novel technologies that target inefficiencies in the pathology workflow optimize cancer care and reduce healthcare costs
Radiant Biotherapeutics is an innovative company focused on developing a modular platform for multi-valent and multi-specific therapeutics. This platform aims to advance antibody engineering by producing multi-functional biologics capable of addressing challenging diseases, including cancer, autoimmune disorders, and infectious diseases. By leveraging enhanced binding power and multi-specificity, Radiant Biotherapeutics seeks to create potent therapeutics that have the potential to significantly improve treatment outcomes for patients. The company is committed to delivering transformative therapies through its cutting-edge approach to antibody technology.
CTRL Therapeutics is a biotechnology company based in Toronto, Canada, focused on the development of cell therapies and innovative diagnostic solutions. The company has created a microfluidic platform that enhances the detection of rare circulating tumor cells. This technology is integral to the development of a cancer liquid biopsy test, which aims to predict how patients will respond to targeted therapies. By enabling the evaluation of protein expression on tumor cells, CTRL Therapeutics seeks to provide valuable insights for doctors in tailoring treatment plans for cancer patients.
HDAX Therapeutics is focused on developing innovative small molecule therapeutics aimed at treating conditions driven by HDAC6, particularly in the realms of cardiovascular and neurological diseases. By addressing the root causes of these conditions, the company seeks to improve patient outcomes significantly. Their approach involves a unique targeted therapeutics platform that utilizes a two-site binding mechanism for HDAC6, which allows for the delivery of treatments that are both safe and effective. This strategy is designed to meet the substantial unmet medical needs associated with neuropathies and cardiometabolic diseases.
Qurcan Therapeutics is focused on developing advanced therapeutic solutions for solid tumors, particularly brain cancers. The company has created a nanotechnology-based drug delivery platform that enhances the precision of cancer treatment by overcoming challenges associated with traditional drug delivery methods. This platform improves the release of therapeutic agents while minimizing liver accumulation, allowing for more effective targeting of difficult-to-reach tumors. Among its innovations is Manganescan®, a theranostic agent that serves as both an MRI contrast agent and a radio-sensitizer, enabling early detection of brain tumors and enhancing the effectiveness of radiation therapy. By facilitating improved drug delivery and modulating the tumor microenvironment, Qurcan Therapeutics aims to increase therapeutic efficacy and extend patient survival in the fight against solid tumor cancers.
Replica Analytics Ltd. is a Canadian company based in Ottawa, established in 2019, that specializes in creating modeling software for generating synthetic data from real clinical datasets. The company employs advanced machine learning techniques to produce privacy-protective synthetic data that retains the statistical properties of actual data, ensuring high utility while adhering to global privacy regulations. In addition to generating this synthetic data, Replica Analytics provides supporting documentation that outlines the utility characteristics of the data, allowing businesses to analyze and utilize data effectively without compromising privacy.
Bridge7 is a company that specializes in AI-powered consultation software aimed at enhancing the quality of care for cancer patients. Founded in 2017 and headquartered in Ontario, Canada, Bridge7's software leverages machine learning algorithms to analyze data from thousands of patients. This capability provides clinical teams with decision-making metrics that facilitate informed consultations regarding cancer treatment options. By offering insights on the quality of cancer care before treatment begins, Bridge7 helps healthcare providers improve clinical efficiency and enhance the overall delivery of care.
Xpan is developing novel and less invasive surgical devices for Minimal Invasive Surgeries. The company was founded in 2017 and based in Toronto, Ontario.
Qurcan Therapeutics is focused on developing advanced therapeutic solutions for solid tumors, particularly brain cancers. The company has created a nanotechnology-based drug delivery platform that enhances the precision of cancer treatment by overcoming challenges associated with traditional drug delivery methods. This platform improves the release of therapeutic agents while minimizing liver accumulation, allowing for more effective targeting of difficult-to-reach tumors. Among its innovations is Manganescan®, a theranostic agent that serves as both an MRI contrast agent and a radio-sensitizer, enabling early detection of brain tumors and enhancing the effectiveness of radiation therapy. By facilitating improved drug delivery and modulating the tumor microenvironment, Qurcan Therapeutics aims to increase therapeutic efficacy and extend patient survival in the fight against solid tumor cancers.
Cellular Analytics is founded upon a proprietary microfluidic platform that enables molecular characterization of cancer at the level of single circulating tumour cells
Qurcan Therapeutics is focused on developing advanced therapeutic solutions for solid tumors, particularly brain cancers. The company has created a nanotechnology-based drug delivery platform that enhances the precision of cancer treatment by overcoming challenges associated with traditional drug delivery methods. This platform improves the release of therapeutic agents while minimizing liver accumulation, allowing for more effective targeting of difficult-to-reach tumors. Among its innovations is Manganescan®, a theranostic agent that serves as both an MRI contrast agent and a radio-sensitizer, enabling early detection of brain tumors and enhancing the effectiveness of radiation therapy. By facilitating improved drug delivery and modulating the tumor microenvironment, Qurcan Therapeutics aims to increase therapeutic efficacy and extend patient survival in the fight against solid tumor cancers.
DNAstack is a cloud-based genomics platform that helps geneticists securely manage, analyze, search, and share genomic datasets in the cloud.
Talon Pharmaceuticals is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines aimed at enhancing patient quality of life and addressing critical health challenges. Utilizing its Multiphore drug design platform, Talon focuses on creating small molecule therapeutics to treat central nervous system disorders and difficult bacterial infections. Among its lead candidates are treatments designed to mitigate levodopa-induced dyskinesia and psychosis in Parkinson's disease, as well as therapies aimed at improving gait. By prioritizing the needs of patients and medical professionals, Talon Pharmaceuticals strives to develop effective solutions that can save lives.
Polumiros is a biomaterials company specializing in the development of a novel immunomodulatory polymer platform technology that manages inflammation and improves healing, restoring patients’ health and quality of life.
16 Bit Inc. is a Toronto-based company that specializes in developing medical image analysis systems, utilizing artificial intelligence to enhance diagnostic capabilities. The company is focused on creating a breast cancer screening triaging algorithm, as well as solutions for neurological emergency detection and pediatric bone age assessment. By leveraging its innovative software, 16 Bit aims to improve the quality, efficiency, and accessibility of healthcare, aiding physicians and radiologists in interpreting medical results more effectively.
Dalriada Therapeutics Inc. is a Canadian company based in Mississauga, established in 2016. It specializes in the development of novel small molecule inhibitors targeting various medical conditions, including oncology, pain modulation, and neurodegenerative and neuroinflammatory disorders. The company employs a TURN-KEY model that integrates research and development with business strategy and intellectual property management, thereby supporting global innovators in the pharmaceutical industry.
DNAstack is a cloud-based genomics platform that helps geneticists securely manage, analyze, search, and share genomic datasets in the cloud.
Radialis develops an organ-targeted positron emission tomography (PET) imaging system aimed at providing high-definition and low-dose imaging solutions for oncology, neurology, and cardiology. Its technology significantly enhances the efficiency of detecting radiotracers compared to conventional PET systems, which allows for improved cancer detection. The system has received broad FDA clearance in the United States for imaging and measuring injected positron-emitting radiopharmaceuticals. Currently, the leading application of this technology is in the high-resolution imaging of primary solid tumors, assisting in treatment planning as a complement to traditional staging PET/CT without requiring additional radiotracer. Furthermore, Radialis is exploring opportunities for early detection of cancer and Alzheimer's disease using low-dose imaging techniques in high-risk populations.
Propellon Therapeutics
Seed Round in 2017
Propellon Therapeutics is developing and commercializing novel cancer therapies targeting the WDR5 protein, essential for assembly of methyltransferase complexes and proper histone modification. The overexpression of WDR5 and resulting deregulation of epigenetic mechanisms are implicated in various cancers and correlated with poor patient survival. Established by FACIT, Propellon’s WDR5 inhibitor platform arises from discoveries, research and innovations originating from OICR.
KA Imaging Inc. is a Canadian company based in Waterloo that focuses on designing and manufacturing advanced X-ray detectors for both medical and non-medical applications. Founded in 2015, the company has developed the world's first portable dual energy subtraction X-ray detector, which enhances the sensitivity of disease identification, including conditions such as pneumonia and fractures. This innovative device, known as Reveal, has received FDA clearance and is sold globally. KA Imaging offers a range of products, including static detectors for identifying faults in infrastructure, dual-energy detectors for baggage screening, dynamic detectors for inspecting moving parts, and specialized mammography detectors. With a team of 20 full-time and 10 part-time employees, the company holds 52 global patents and 17 issued US patents, emphasizing its commitment to advancing X-ray imaging technology across various sectors.
Turnstone Biologics Inc. is a biotechnology company based in Ottawa, Canada, with an additional office in New York. Founded in 2015, it is dedicated to developing innovative viral immunotherapies aimed at improving survival rates for cancer patients. The company's lead product, RIVAL-01, utilizes a vaccinia virus backbone to deliver three key immunomodulators: Flt3 ligand, anti-CTLA-4 antibody, and IL-12 cytokine. These components are designed to enhance immune activity and reprogram the tumor microenvironment for optimal tumor eradication. Additionally, Turnstone Biologics is advancing next-generation tumor-infiltrating lymphocyte (TIL) therapies, which involve selecting and expanding the most effective T cells from a patient’s tumor to enhance the body’s immune response against solid tumors. Through these approaches, Turnstone aims to deliver breakthrough immunotherapies for cancer treatment.
FDA cleared device for early detection of Barrett’s Esophagus and other Upper GI diseases such as cancer and H-pylori. Opportunity to launch the FDA 510k clearedNon-endoscopic swallowable screening device for esophageal bottle-brush cellular retrieval for use with new Genome Sequencing diagnostic tests (Biomarkers) that are expected to become mass "out-patient" screening tests used for the early detection of Barrett’s Esophagus and other diseases.
Turnstone Biologics Inc. is a biotechnology company based in Ottawa, Canada, with an additional office in New York. Founded in 2015, it is dedicated to developing innovative viral immunotherapies aimed at improving survival rates for cancer patients. The company's lead product, RIVAL-01, utilizes a vaccinia virus backbone to deliver three key immunomodulators: Flt3 ligand, anti-CTLA-4 antibody, and IL-12 cytokine. These components are designed to enhance immune activity and reprogram the tumor microenvironment for optimal tumor eradication. Additionally, Turnstone Biologics is advancing next-generation tumor-infiltrating lymphocyte (TIL) therapies, which involve selecting and expanding the most effective T cells from a patient’s tumor to enhance the body’s immune response against solid tumors. Through these approaches, Turnstone aims to deliver breakthrough immunotherapies for cancer treatment.
Privacy Analytics allows healthcare organizations to quickly and easily apply a responsible de-identification methodology that ensures individual privacy and legal compliance.
Triphase Accelerator is a privately held drug development accelerator that acquires and develops novel therapeutics. Triphase in-licenses clinically enabled oncology assets with high-value potential and develops them in a shared risk model to proof of concept (POC), then out-licenses or sells the product to realize value. Triphase has formed a strategic partnership with Celgene Corporation to enable the rapid development of proof of concept in important new cancer therapeutics of mutual interest. The Triphase management team is deeply knowledgeable with significant experience in drug development. Together with the founding organizations Ontario Institute of Cancer Research (OICR) and MaRS Innovation, and supported by MaRS Discovery District along with strategic oncology partnerships, Triphase has formed a unique partnership to produce proof-of-concept data for investors, partners, regulators, payers, and ultimately prescribers and patients.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.